Keele Research Repository

Article

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Haviland, JS (2023) Hypofractionation: The standard for external beam breast irradiation. Breast, 69. 410 - 416.

Fernando, IN, Lax, S, Bowden, SJ, Ahmed, I, Steven, JH, Churn, M, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Agrawal, RK, Canney, P, Stevens, A and Rea, DW (2023) Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology.

Oswald, AJ, Symeonides, SN, Wheatley, D, Chan, S, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Chisholm, EM, Welsh, M, Hill, R, Hopcroft, LEM, Barrett-Lee, P and Cameron, DA (2023) Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment.

Glynn, D, Bliss, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Coles, CE, Wheatley, D, Haviland, JS, Kirby, AM, Longo, F, Faria, R, Yarnold, JR and Griffin, S (2022) Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Research and Treatment. 1 - 12.

Wheatley, D, Haviland, J, Patel, J, Sydenham, M, Alhasso, A, Chan, C, Cleator, S, Coles, C, Donovan, E, Kirby, A, Kirwan, C, Nabi, Z, Sawyer, E, Somaiah, N, Syndikus, I, Venables, K, Yarnold, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Bliss, J (2022) First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Radiotherapy and Oncology, 170. S75 - S76.

Bundred, N, Porta, N, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Cramer, A, Hanby, A, Shaaban, AM, Rakha, EA, Armstrong, A, Cutress, RI, Dodwell, D, Emson, MA, Evans, A, Hartup, SM, Horgan, K, Miller, SE, McIntosh, SA, Morden, JP, Naik, J, Narayanan, S, Ooi, J, Skene, AI, Cameron, DA and Bliss, JM (2022) Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 28 (7). 1323 - 1334.

Meattini, I, Becherini, C, Boersma, L, Kaidar-Person, O, Marta, GN, Montero, A, Offersen, BV, Aznar, MC, Belka, C, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Dicuonzo, S, Franco, P, Krause, M, MacKenzie, M, Marinko, T, Marrazzo, L, Ratosa, I, Scholten, A, Senkus, E, Stobart, H, Poortmans, P and Coles, CE (2022) European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncology, 23 (1). e21 - e31.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Kirby, AM, Somaiah, N, Wheatley, DA, Bliss, JM and Yarnold, JR (2021) Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology.

Lewis, P, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Coles, C, Griffin, S, Locke, I, Roques, T and Working Group, Breast Radiotherapy Consensus (2021) Moving Forward Fast with FAST-Forward. Clinical Oncology.

Obeng-Gyasi, S, Coles, CE, Jones, J, Sacks, R, Lightowlers, S, Bliss, JM, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Kirby, AM and Kalinsky, K (2021) When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology educational book, 41. 1 - 11.

Hoskin, P, Popova, B, Schofield, O, Brammer, C, Robinson, M, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Madhavan, K, Illidge, T, Gallop-Evans, E, Syndikus, I, Clifton-Hadley, L and Kirkwood, AA (2021) 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, 22 (3). pp. 332-340.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA and Yarnold, JR (2020) Breast cancer radiation therapy - Authors' reply. Lancet, 396 (10262). 1559 - 1560.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.

Brunt, AM, Haviland, JS, Sydenham, M, Agrawal, RK, Algurafi, H, Alhasso, A, Barrett-Lee, P, Bliss, P, Bloomfield, D, Bowen, J, Donovan, E, Goodman, A, Harnett, A, Hogg, M, Kumar, S, Passant, H, Quigley, M, Sherwin, L, Stewart, A, Syndikus, I, Tremlett, J, Tsang, Y, Venables, K, Wheatley, D, Bliss, JM and Yarnold, JR (2020) Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. Journal of Clinical Oncology, 38 (28). pp. 3261-3272.

Manoj, GS, Kabeer, KK, Jafferbhoy, S, Marla, S, Soumian, S, Misra, V, Narayanan, S and Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 (2020) Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82. pp. 251-258.

Coles, CE, Aristei, C, Bliss, J, Boersma, L, Brunt, AM, Chatterjee, S, Hanna, G, Jagsi, R, Kaidar Person, O, Kirby, A, Mjaaland, I, Meattini, I, Luis, AM, Marta, GN, Offersen, B, Poortmans, P and Rivera, S (2020) International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology, 32 (5). 279 - 281.

Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, RD, Park, YH, Hall, PS, Perren, T, Stein, RC, Mangel, L, Ferrero, J-M, Phillips, M, Conibear, J, Cortes, J, Foxley, A, de Bruin, EC, McEwen, R, Stetson, D, Dougherty, B, Sarker, S-J, Prendergast, A, McLaughlin-Callan, M, Burgess, M, Lawrence, C, Cartwright, H, Mousa, K and Turner, NC (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). 423 - 433.

Fernando, IN, Bowden, SJ, Herring, K, Brookes, CL, Ahmed, I, Marshall, A, Grieve, R, Churn, M, Spooner, D, Latief, TN, Agrawal, RK, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Stevens, A, Goodman, A, Canney, P, Bishop, J, Ritchie, D, Dunn, J, Poole, CJ and Rea, DW (2020) Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142. pp. 52-61.

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Ruiz, I, Perelló, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Máhr, K, Schenker, M, Sohn, J, Lee, KS, Shepherd, CJ, Oelmann, E, Sarker, S-J, Prendergast, A, Marosics, P, Moosa, A, Lawrence, C, Coetzee, C, Mousa, K and Cortés, J (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5 (11). 1556 - 1556.

Coles, CE, Griffin, CL, Kirby, AM, Haviland, JS, Titley, JC, Benstead, K, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Chan, C, Ciurlionis, L, Din, OS, Donovan, EM, Eaton, DJ, Harnett, AN, Hopwood, P, Jefford, ML, Jenkins, PJ, Lee, CE, McCormack, M, Sherwin, L, Syndikus, I, Tsang, Y, Twyman, NI, Ventikaraman, R, Wickers, S, Wilcox, MH, Bliss, JM and Yarnold, JR (2019) Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Cancer Research, 79 (4).

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Algurafi, H, Alhasso, A, Bliss, P, Bloomfield, D, Emson, M, Goodman, A, Harnett, A, Passant, H, Tsang, YM, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics, 102 (5). 1603 -1604.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Rada, Z, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. British Journal of Cancer, 119 (11). 41 - 41.

Winters, ZE, Horsnell, J, Elvers, KT, Maxwell, AJ, Jones, LJ, Shaaban, AM, Schmid, P, Williams, NR, Beswick, A, Greenwood, R, Ingram, JC, Saunders, C, Vaidya, JS, Esserman, L, Jatoi, I and Brunt, AM (2018) Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 2 (4). 162 - 174.

Yoganayagam, N, Tripathy, A, Exton, S, Rawet, T, Wu, KS, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Gahir, D and Jegannathen, A (2018) Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. European Journal of Cancer, 92. S119 - S119.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Al-hasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Zotova, R, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127 (S1). S311 -S312.

Coles, CE, Griffin, CL, Kirby, AM, Titley, J, Agrawal, RK, Alhasso, A, Bhattacharya, IS, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, C, Donovan, EM, Emson, MA, Harnett, AN, Haviland, JS, Hopwood, P, Jefford, ML, Kaggwa, R, Sawyer, EJ, Syndikus, I, Tsang, YM, Wheatley, DA, Wilcox, M, Yarnold, JR, Bliss, JM and Trialists, IMPORT (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390 (10099). 1048 - 1060.

Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.

Megias, D, Sydenham, M, Wheatley, D, Maclennan, M, Spezi, E and Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 (2017) Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. Radiotherapy and Oncology, 123. S136 - S137.

Coles, C, Griffin, C, Kirby, A, Agrawal, R, Alhasso, A, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, H, Donovan, E, Emson, M, Harnett, A, Haviland, J, Hopwood, P, Jefford, M, Kaggwa, R, Sawyer, E, Sybdikus, I, Tsang, Y, Wheatley, D, Wilcox, M, Yarnold, J and Bliss, J (2017) Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology, 123 (S1). S162 -S163.

Price, L and Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 (2017) Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? European Journal of Hospital Pharmacy: Science and Practice, 25 (6). 331 - 333.

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP and Bliss, JM (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120 (1). pp. 114-118.

Earl, HM, Hiller, H, Vallier, A-L, Bowden, SJ, Jordan, SD, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, DA, Agrawal, R, Fernando, I, Brunt, AM, O'Reilly, SM, Crawford, SM, Rea, DW, Simmonds, P, Mansi, JL, Stanley, A, McAdam, K, Foster, L, Leonard, RCF, Twelves, CJ, Cameron, D, Bartlett, JMS, Pharoah, P, Provenzano, E, Caldas, C and Poole, CJ (2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 107 (8). pp. 1257-1267.

Conference or Workshop Item

Coles, C, Haviland, JS, Kirby, AM, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Chan, C, Donovan, EM, Eaton, DJ, Griffin, CL, Hopwood, P, Jefford, ML, Lightowlers, S, Rajapakse, C, Sawyer, E, Stones, L, Syndikus, I, Titley, JC, Tsang, Y, Twyman, NI, Bliss, JM and Yarnold, JR (2021) IMPORT HIGH trial: Dose escalated simultaneous integrated boost radiotherapy in early breast cancer. In: ESTRO 2021, 28-31 August 2021, Madrid, Spain & Online.

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Cabrero, IR, Perello, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Mahr, K, Schenker, M, Sohn, JH, Lee, KS, Sarker, S-J, Coetzee, C, Mousa, K and Castan, JC (2018) MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. In: 2017 San Antonio Breast Cancer Symposium, December 5-9 2017, San Antonio, Texas.